Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trastuzumab plus docetaxel in trastuzumab-pretreated HER2-positive gastric cancer (T-CORE1203)
jRCTs021180015Phase 2Completed
- Sponsor
- Tohoku Clinical Oncology Research and Educational Society
- Start
- May 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and docetaxel in gastric adenocarcinoma, sponsored by Tohoku Clinical Oncology Research and Educational Society. Primary endpoint: Overall response rate. Started May 2013; status: completed.
02
Drugs
trastuzumabdocetaxel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs021180015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180015.